However, CLCA4 did confer a statistically significant relapse-free survival advantage to patients with Luminal B breast cancers, a subtype that is generally low in estrogen and progesterone receptors and prone to relapse (Figure 8B) [3]. Here, CLCA4 is linked to breast cancer.